Tests HM17321 safety in healthy and obese adults
Tests a new drug, HM17321, in healthy and obese adults to check safety.
Key facts
- Who runs it
- Hanmi Pharmaceutical Company Limited
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Registry title
- A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 90 people, planned
- Started
- 6 Nov 2025
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- HM17321
- Placebo of HM17321
- Record updated
- 4 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-65 who are either healthy (Part A) or healthy and obese (Part B), to test the safety of the drug HM17321.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Part A: healthy people with BMI from 20 to 27 kg/m². Part B: obese people with BMI from 30 to 45 kg/m².
- Earlier treatment
- Stable body weight (less than 5% change) in the past 3 months. In Part B, no weight control treatments or blood pressure medicines in the 3 months before screening.
Main reasons for not taking part
- Past bariatric (weight loss) surgery
- Positive test for hepatitis B, hepatitis C or HIV
- Pregnant, planning pregnancy or breastfeeding
- Diabetes (Part B)
- Clinically significant heart, liver, pancreas or kidney problems
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adults aged 18-65 years
- Part A: Healthy participants with BMI ≥20 kg/m² and ≤27 kg/m² at screening
- Part B: Healthy obese participants with BMI ≥30 kg/m² and ≤45 kg/m² at screening
- Stable body weight (<5% change) in the past 3 months
- Able and willing to provide written informed consent
- Male participants must use contraception or remain abstinent from women of childbearing potential
- Female participants must not be pregnant or breastfeeding and use highly effective contraception if of childbearing potential
Who cannot take part
- Use of any investigational product within 30 days or 5 half-lives (whichever is longer) prior to screening
- History of any bariatric procedure
- Uncontrolled thyroid disease (TSH >6.0 or <0.4 mIU/L)
- Positive test for hepatitis B, hepatitis C, or HIV at screening
- History of drug or alcohol abuse within defined timeframes (e.g., alcohol >14 standard units/week in past year, or positive drug screen)
- Abnormal liver function or clinically significant liver disease; Part A: ALT or AST ≥ ULN, or total bilirubin ≥ ULN; Part B: ALT or AST >2× ULN, or total bilirubin >1.5× ULN
- Abnormal pancreatic function; Part A: amylase or lipase ≥ ULN; Part B: amylase or lipase >3× ULN
- Clinically significant cardiovascular disorders (e.g., myocardial infarction, congestive heart failure, long QT syndrome)
- Abnormal renal function (eGFR <60 mL/min/1.73 m²)
- Additional Exclusion Criteria for Part B; HbA1c ≥6.5% or a history of diabetes mellitus (type 1 or type 2); Obesity induced by other endocrine disorders (e.g., Cushing syndrome); Use of weight control treatments (e.g., GLP-1 receptor agonists or other anti-obesity medications) and antihypertensive medications within 3 months prior to screening; Use of any lipid-lowering medications, unless on a stable dose for at least 3 months prior to screening
- Women who are pregnant, planning to become pregnant, or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Medpace Clinical Pharmacology UnitCincinnati, United StatesContact: Leela Vrishabhendra (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
The 2 groups in the trial
- HM17321Treatment being tested
- PlaceboPlacebo, for comparison
Treatment: Placebo of HM17321
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy and Obese Participants
- Plain-language title
- Tests HM17321 safety in healthy and obese adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07219589, who can take part
- Record updated
- 4 May 2026